Advances in vaccination against tick-borne encephalitis

References

• Burke DS, Monath TP. Flaviviruses. In: Fields Virology (4th Edition). Knipe DM, Howley PM, Griffin DE (Eds). Lippincott Williams and Wilkins, NY, USA (2001).
   Google Scholar
• Süss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine21, 19–35 (2003).
   Web of Science ®Google Scholar
• Kunz C. TBE vaccination and the Austrian experience. Vaccine21(Suppl. 1), 50–55 (2003).
   PubMed Web of Science ®Google Scholar
• Süss J, Klaus C, Gerstengarbe FW, Werner PC. What makes ticks tick? Climate change, ticks, and tick-borne diseases. J. Travel Med.15(1), 39–45 (2008).
   PubMed Web of Science ®Google Scholar
• Randolph SE. Evidence that climate change has caused “emergence” of tick-borne diseases in Europe? Int. J. Med. Microbiol.293(Suppl. 37), 5–15 (2004).
   PubMed Web of Science ®Google Scholar
• Sumilo D, Bormane A, Asokliene L et al. Socio–economic factors in the differential upsurge of tick-borne encephalitis in Central and Eastern Europe. Rev. Med. Virol.18(2), 81–95 (2008).
   PubMed Web of Science ®Google Scholar
• Charrel RN, Attoui H, Butenko AM et al. Tick-borne virus diseases of human interest in Europe. Clin. Microbiol. Infect.10, 1040–1055 (2004).
   PubMed Web of Science ®Google Scholar
• Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. J. Clin. Infect. Dis.28, 882–890 (1999).
   PubMed Web of Science ®Google Scholar
• Waldvogel K, Bossart W, Huisman T et al. Severe tick-borne encephalitis following passive immunisation. Eur. J. Pediatr.155, 775–779 (1996).
   PubMedGoogle Scholar
• Aendekerk RP, Schrivers AN, Koehler PJ. Tick-borne encephalitis complicated by a polio-like syndrome following a holiday in Central Europe. Clin. Neurol. Neurosurg.98, 262–264 (1996).
   PubMedGoogle Scholar
• McNeil JG, Lednar WM, Stansfield SK et al. Central European tick-borne encephalitis: assessment of risk for persons in the armed services and vacationers. J. Infect. Dis.152, 650–651 (1985).
   PubMedGoogle Scholar
• Rendi-Wagner P. Risk and prevention of tick-borne encephalitis in travelers. J. Travel Med.11(5), 307–312 (2004).
   PubMed Web of Science ®Google Scholar
• Popov OV, Sumarkov AA, Shkolnik RY et al. A study of the reactogenic and antigenic potency of dried chromatographic purified concentrated inactivated vaccine against tick-borne encephalitis. Zh. Mikrobiol. Epidemiol. Immunobiol.6, 34–39 (1985).
   Google Scholar
• Kunz C, Hofmann H, Stary A. Field studies with a new tick-borne encephalitis (TBE) vaccine. Zentralbl. Bakt. [Orig. A]243(1), 141–144 (1976).
   Google Scholar
• Klockmann U, Bock H, Franke V et al. Preclinical investigation of the safety, immunogenicity and efficacy of a purified, inactivated tick-borne encephalitis vaccine. J. Biol. Standard17, 331–342 (1989).
   PubMedGoogle Scholar
• Niedrig M, Klockmann U, Lang W et al. Monoclonal antibodies directed against tick-borne encephalitis virus with neutralizing activity in vivo. Acta Virol.38, 141–149 (1994).
   PubMedGoogle Scholar
• Ecker M, Allison SL, Meixner T et al. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J. Gen. Virol.80, 179–185 (1999).
   PubMed Web of Science ®Google Scholar
• Holzmann H, Vorobyova MS, Ladyzhenskaya IP et al. Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes. Vaccine10, 345–349 (1992).
   PubMedGoogle Scholar
• Klockmann U, Krivanec K, Stephenson JR, Hilfenhaus J. Protection against European isolates of tick-borne encephalitis virus after vaccination with a new tick-borne encephalitis vaccine. Vaccine9, 210–212 (1991).
   PubMedGoogle Scholar
• Barret PN, Schober-Bendixen S, Ehrlich HJ. History of TBE vaccines. Vaccine21(Suppl.), S41–S49 (2003).
   Google Scholar
• Zent O, Beran J, Jilg W et al. Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults. Vaccine21, 738–741 (2003).
   PubMed Web of Science ®Google Scholar
• Zent O, Hennig R, Banzhoff A, Bröker M. Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers. J. Travel Med.12(2), 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Zent O, Banzhoff A, Hilbert AK, Meriste S, Sluzewski W, Wittermann CH. Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Vaccine21(25–26), 3584–3592 (2003).
   PubMed Web of Science ®Google Scholar
• Loew-Baselli A, Konior R, Pavlova BG et al. FSME-IMMUN Study Group. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large Phase 3 clinical studies. Vaccine24(24), 5256–5263 (2006).
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Pavlova BG, Fritsch S et al. Randomized, Phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine22(2), 217–223 (2003).
   PubMed Web of Science ®Google Scholar
• Marth E, Kleinhappl B. Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine20, 532–537 (2001).
   PubMed Web of Science ®Google Scholar
• Marth E, Kleinhappl B, Jelovcan S. Stimulation of the immune system by different TBE-virus vaccines. Int. J. Med. Microbiol.293(Suppl. 37), 139–144 (2004).
   PubMedGoogle Scholar
• Zent O, Hennig R. Post-marketing surveillance of immediate allergic reactions: polygeline-based vs. polygeline-free pediatric TBE vaccine. Vaccine23, 579–584 (2004).
   PubMed Web of Science ®Google Scholar
• Pavlova BG, Loew-Baselli A, Fritsch S et al. Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN “NEW” in children: results of post-marketing surveillance. Vaccine21(7–8), 742–745 (2003).
   PubMedGoogle Scholar
• Schöndorf I, Beran J, Cizkova D, Lesna V, Banzhoff A, Zent O. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine25(8), 1470–1475 (2007).
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Kundi M, Zent O et al. Persistence of protective immunity following vaccination against tick-borne encephalitis – longer than expected? Vaccine22(21–22), 2743–2749 (2004).
   PubMedGoogle Scholar
• Zent O, Plentz A, Schwarz TF et al. TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary? Vaccine23(3), 312–315 (2004).
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B, Kollaritsch H. Seroprotection 4 years following booster vaccination against tick-borne encephalitis. Int. J. Med. Microbiol. (2008) (In press).
   Google Scholar
• Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine25(43), 7559–7567 (2007).
   PubMed Web of Science ®Google Scholar
• Bender A, Jäger G, Scheuerer W, Feddersen B, Kaiser R, Pfister H. Two severe cases of tick-borne encephalitis despite complete active vaccination – the significance of neutralizing antibodies. J. Neurol.251(3), 353–354 (2004).
   PubMedGoogle Scholar
• Kleiter I, Jilg W, Bogdahn U, Steinbrecher A. Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination. Infection35(1), 26–29 (2007).
   PubMedGoogle Scholar
• Schoendorf I, Ternak G, Oroszlàn G, Nicolay U, Banzhoff A, Zent O. Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Hum. Vaccin.3(2), 42–47 (2007).
   PubMed Web of Science ®Google Scholar
• Eder G, Kollaritsch H. Antigen dependent adverse reactions and seroconversion of a tick borne encephalitis vaccine in children. Vaccine21, 3575–3583 (2003).
   PubMed Web of Science ®Google Scholar
• Hofmann H. After vaccination for tick-borne encephalitis must onset of neurologic disorders be expected? Wien. Klin. Wochenschr.107(17), 509–515 (1995).
   PubMedGoogle Scholar
• Confavreux C, Suissa S, Saddier P et al. Vaccinations and the risk of relapse in multiple sclerosis. N. Engl. J. Med.344, 319–326 (2001).
   PubMed Web of Science ®Google Scholar
• Baumhackl U, Franta C, Retzl J et al. A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine21, S56–S61 (2003).
   Web of Science ®Google Scholar
• Mandl CW, Holzmann H, Meixner T et al. Spontaneous and engineered deletions in the noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus. J. Virol.72, 2132–2140 (1998).
   PubMed Web of Science ®Google Scholar
• Mandl CW, Allinson SL, Holzmann H, Meixner T, Heinz FX. Attenuation of tick-borne encephalitis virus by structure-based site specific mutagenesis of a putative flavivirus receptor binding site. J. Virol.74, 9601–9609 (2000).
   PubMed Web of Science ®Google Scholar
• Pletnev AG, Bray M, Lai CJ. Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J. Virol.67, 4956–4963 (1993).
   PubMed Web of Science ®Google Scholar
• Pletnev AG, Bray M, Huggins J, Lai CJ. Construction and characterisation of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc. Natl Acad. Sci. USA89, 10532–10536 (1992).
   PubMed Web of Science ®Google Scholar
• Pletnev AG, Men R. Attenuation of the Langat tick-borne flavivirus by chimerisation with mosquito-borne flavivirus dengue type 4. Proc. Natl Acad. Sci. USA95, 1746–1751 (1998).
   PubMedGoogle Scholar
• Kofler RM, Heinz FX, Mandl CW. Capsid protein C of tickborne encephalitis virus tolerates large internal deletions and is a favourable target for attenuation of virulence. J. Virol.76, 3534–3543 (2002).
   PubMedGoogle Scholar